KR940019712A - Purified streptogramine and its preparation - Google Patents

Purified streptogramine and its preparation Download PDF

Info

Publication number
KR940019712A
KR940019712A KR1019940002667A KR19940002667A KR940019712A KR 940019712 A KR940019712 A KR 940019712A KR 1019940002667 A KR1019940002667 A KR 1019940002667A KR 19940002667 A KR19940002667 A KR 19940002667A KR 940019712 A KR940019712 A KR 940019712A
Authority
KR
South Korea
Prior art keywords
group
streptogramin
component
radical
subcomponent
Prior art date
Application number
KR1019940002667A
Other languages
Korean (ko)
Other versions
KR100333185B1 (en
Inventor
앤거 빠스칼
보나보 버트란
깔레 알랭
르페브르 빠뜨릭
Original Assignee
프랑소와즈 로브조아
로오느-푸우랜크 로레르 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9301787A external-priority patent/FR2701709B1/en
Application filed by 프랑소와즈 로브조아, 로오느-푸우랜크 로레르 소시에테 아노님 filed Critical 프랑소와즈 로브조아
Publication of KR940019712A publication Critical patent/KR940019712A/en
Application granted granted Critical
Publication of KR100333185B1 publication Critical patent/KR100333185B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06182—Dipeptides with the first amino acid being heterocyclic and Pristinamycin II; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

하기 구조식의 스트렙토그라민의 하나 이상의 B군 성분 :At least one group B component of streptogramin of the formula:

(상기식에서, A1은 하기 구조식 :Wherein A 1 is the following structural formula:

의 라디칼이고, 이때 R'는 OH이며, Y는 H, 메틸아미노 라디칼 또는 디메틸아미노 라디칼이고, R은 에틸 라디칼이거나, R'가 수소 원자인 경우 R은 또한 -CH3일 수 있고 R1및 R2는 H이거나, 대안으로 A1은 하기 구조식 :Wherein R 'is OH, Y is H, methylamino radical or dimethylamino radical, R is an ethyl radical, or if R' is a hydrogen atom, R can also be -CH 3 and R 1 and R 2 is H, or alternatively A 1 is

의 라디칼이고, R은 이소부틸 라디칼이고, R1은 OH이며 R2는 -CH3임) 및 하기 구조식의 스트렙코그라민의 하나 이상의 A군 부성분 ;And R is an isobutyl radical, R 1 is OH and R 2 is -CH 3 ) and at least one group A subcomponent of strepcogramin of the following structural formula;

(상기식에서, R"는 H, 또는 메틸 또는 에틸 라디칼임)의 배합물로 구성된, 공결정물, 공침전물 또는 미쇄분쇄 물리적 혼합물 형태의 정제형 스트렙토그라민은 유용한 항균성 활성을 갖는다.Tablets of streptogramamine in the form of co-crystals, co-precipitates or pulverized physical mixtures, consisting of a combination of (wherein R '' is H, or methyl or ethyl radicals) have useful antimicrobial activity.

Description

정제형 스트렙토그라민 및 그의 제법Purified streptogramine and its preparation

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

하기 구조식의 스트렙토그라민의 하나 이상의 B군 성분 :At least one group B component of streptogramin of the formula: (상기식에서, A1은 하기 구조식 :Wherein A 1 is the following structural formula: 의 라디칼이고, 이때 R'는 수소원자 또는 히드록시 라디칼이며, Y는 수소원자, 메틸아미노 라디칼 또는 디메틸아미노 라디칼이고, R은 에틸 라디칼이거나, R'가 수소 원자인 경우 R은 또한 메틸 라디칼이고, R1및 R2는 각각 수소원자이거나, 또는 A1은 하기 구조식 :Wherein R 'is a hydrogen atom or a hydroxy radical, Y is a hydrogen atom, a methylamino radical or a dimethylamino radical, R is an ethyl radical or when R' is a hydrogen atom, R is also a methyl radical, R 1 and R 2 are each hydrogen or A 1 is the following structural formula: 의 라디칼이고, R은 이소 부틸 라디칼이고, R1은 히드록실 라디칼이며 R2는 메틸 라디칼임) 및 하기 구조식의 스트렙토그라민의 하나 이상의 A군 부성분;And R is an isobutyl radical, R 1 is a hydroxyl radical and R 2 is a methyl radical) and at least one group A subcomponent of streptogamine of the formula: 상기식에서, R"는 수소 원자, 또는 메틸 또는 에틸 라디칼임)의 배합물로 구성된, 공결정물, 공침전물 또는 미세 분쇄 물리적 혼합물 형태의 정제형 스트렙토그라민.Wherein R '' is a hydrogen atom, or a mixture of methyl or ethyl radicals), tableted streptogramin in the form of a co-crystal, co-precipitate or finely ground physical mixture. 제1항에 있어서, 6% 이하의 불순물을 함유하는 정제형 스트렙토 그라민.The tablet streptogramamine according to claim 1, which contains up to 6% impurities. 제1항 또는 2항에 있어서, 스트렙토그라민의 상기 B군 성분 및 스트렙토그라민의 상기 A군 부성분의 상대비가 10:90 내지 90:10 중량비인 정제형 스트렙토그라민.The tablet type streptogramamine according to claim 1 or 2, wherein the relative ratio of the Group B component of streptogamine and the Group A subcomponent of streptogramin is 10:90 to 90:10 by weight. 제3항에 있어서, 스트렙토그라민의 상기 B군 성분 및 스트렙토 그라민의 상기 A군 부성분의 상대비가 20:80 내지 80:20 중량비인, 공침전 또는 미세 분쇄 물리적 혼합물 형태의 정제형 스트렙토그라민.4. The tablet streptogramin according to claim 3, wherein the relative ratio of the Group B component of streptogramin and the Group A subcomponent of streptogramin is in a 20:80 to 80:20 weight ratio. 제1 또는 2항에 있어서, 1:2 정도의 몰비의 스트렙토그라민의 하나 이상의 상기 B군 성분 및 스트렙토그라민의 하나 이상의 상기 A군 부성분의 공결성 화합물 형태의 정제형 스트렙토그라민.The tablet streptogramamine according to claim 1 or 2, in the form of a covalent compound of at least one of the Group B components of streptogramin at a molar ratio of about 1: 2 and at least one Group A subcomponent of streptogramine. 스트렙토그라민의 상기 B군 성분(들)과 스트렙토그라민의 상기 A군 성분(들)을 공결정화하고, 만일 필요하다면 얻어진 공결정 화합물을 적당한 A군 또는 B군 성분(들)과 배합하여 원하는 비의 배합물을 얻는 것으로 구성된, 제 1 항에 따른 정제형 스트랩토그라민의 제조 방법.Co-crystallizing the Group B component (s) of streptogamine and the Group A component (s) of streptogramin, and if necessary combining the obtained co-crystal compound with a suitable Group A or Group B component (s) A process for the preparation of tablets of straptogramin according to claim 1, consisting of obtaining a blend. 스트렙토그라민의 하나 이상의 B군 성분과 스트렙토그라민의 A군 부성분의 공결성 화합물을 제조하고 산 매질내에서 처리하므로써 B군 성분(들)을 제거하는 것으로 구성된, 제1항에서 청구된 바의 스트렙토그라민의 A군 부성분의 정제 방법.Streptogra as claimed in claim 1, consisting of removing the group B component (s) by preparing a covalent compound of at least one group B component of streptogramin and a group A subcomponent of streptogramin and treating in an acid medium. Purification method of Min group A subcomponent. 정제형의 하기 구조식의 스트렙토그라민의 A군 성분 :Group A component of streptogramin of the following structural formula in tablet form: 상기식에서, R"는 수소원자 또는 에틸 라디칼이다.Wherein R ″ is a hydrogen atom or an ethyl radical. 제1항에서 청구된 바의 스트렙토그라민 또는 이들의 유도체의 하나 이상의 B군 성분 및 스트렙토그라민의 하나 이상의 A군 부성분으로 구성된 공결정화 화합물.A co-crystallization compound consisting of at least one group B component of streptogramin or a derivative thereof as claimed in claim 1 and at least one group A subcomponent of streptogramin. 제1 또는 2항에 따른 정제형 스트렙토그라민으로 구성된 항균성 제약학적 조성물.An antimicrobial pharmaceutical composition consisting of tablet streptogamine according to claim 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940002667A 1993-02-17 1994-02-15 Purified form of streptogramins and its preparation KR100333185B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9301787 1993-02-17
FR9301787A FR2701709B1 (en) 1993-02-17 1993-02-17 Purified form of streptogramins, its preparation and the pharmaceutical compositions containing it.

Publications (2)

Publication Number Publication Date
KR940019712A true KR940019712A (en) 1994-09-14
KR100333185B1 KR100333185B1 (en) 2002-08-21

Family

ID=34639851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940002667A KR100333185B1 (en) 1993-02-17 1994-02-15 Purified form of streptogramins and its preparation

Country Status (4)

Country Link
JP (1) JP3718521B2 (en)
KR (1) KR100333185B1 (en)
PE (1) PE11395A1 (en)
UY (1) UY23821A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016055278A (en) * 2014-09-12 2016-04-21 竹上　敬三 Dividing method of cocrystal

Also Published As

Publication number Publication date
JP3718521B2 (en) 2005-11-24
JP2005132849A (en) 2005-05-26
UY23821A1 (en) 1995-02-17
KR100333185B1 (en) 2002-08-21
PE11395A1 (en) 1995-07-14

Similar Documents

Publication Publication Date Title
KR830006174A (en) Bronchial Anticonvulsant Compounds
EP0393493A3 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US4981869A (en) Xanthates as antitumor agents
ES480605A1 (en) o-Substituted (+)-cyanidan-3-ol derivatives, method for their preparation, as well as pharmaceutical compositions containing these compounds and their preparation.
KR910002802A (en) Derivatives of 1,2,3,4-tetrahydro-9-acridinamine
CN115260186B (en) VMAT2 inhibitor and preparation method and application thereof
RU94046141A (en) Substituted(arylalkoxybenzyl)aminopropaneamide derivatives, processes for preparation thereof, and pharmaceutical composition
KR940019712A (en) Purified streptogramine and its preparation
KR890001965A (en) Spurgualine Related Derivatives
IE780377L (en) 14,15-dihydro-20,21-dinoreburnamenine-14-ols
AU558261B2 (en) Dialkylaminoalkyoxybenzylalcohol derivatives
US20130331390A1 (en) Nitrogen-Containing Biphenyl Compounds, Pharmaceutical Compositions of Same, Preparation Methods and Anti-HIV-1 Uses Thereof
DE3043437C2 (en)
KR930017882A (en) Amino benzoic acid derivatives
CA2089207A1 (en) Amphoteric Tricyclic Compound
KR920005719A (en) Rabdan and its manufacturing method
JPH03118334A (en) Hepatopathic inhibitor
KR950703955A (en) Pharmaceutical Uses of Terpyridine Derivatives
KR930023328A (en) N-methyldeacetylcol hisinamide derivative
KR880013896A (en) Benzofuro [3,2-C] quinoline compound
AU2014361790B2 (en) Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
DE3017026A1 (en) ISOPRENYLAMINE AND ITS ACID ADDITION SALTS AND ANTIVIRUS CONTAINERS THEREFORE FOR VERTEBLE ANIMALS
CA1100877A (en) Antiviral agent
ES8708213A1 (en) Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient.
GB2074165A (en) Nonaprenylamine derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110318

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee